Evaluating the Impact of Myriad on the Biotech Industry

07/24/2013 12:00 p.m. - 01:30 p.m. PDT

Patent Litigation, Patent Counseling + Prosecution, and Life Sciences

Morrison & Foerster
755 Page Mill Road
Palo Alto, CA 94304

Catherine M. Polizzi and Matthew I. Kreeger

Matthew I. Kreeger and Catherine M. Polizzi

Webinar

Jennifer Dubman
jdubman@mofo.com
(415) 268-6742

To listen to the webcast, click here.

In a unanimous decision on June 13, 2013, the U.S. Supreme Court ruled that isolated, naturally occurring human gene sequences are a product of nature and thus not patent-eligible subject matter. The Court did, however, hold that synthetically created DNA (cDNA) is patent-eligible because it is not naturally occurring.

As the biotechnology industry digests the Myriad decision and assesses its impact on patent portfolios, this program will discuss the significant effects that the decision will have on the future of patents to inventions derived from naturally occurring substances and the important questions you may want to consider.

Topics Will Include:

  • An industry perspective of the impact of Myriad
  • Practical insight into adjusting existing prosecution and litigation strategies in light of Myriad
  • Solutions for developing and implementing new strategies going forward

Speakers:

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2017 Morrison & Foerster LLP. All rights reserved.